Abstracts tagged "Biomarkers"

Abstract Number: 2917 • 2017 ACR/ARHP Annual Meeting
Neutrophil Activation in Rheumatoid Arthritis – Potential Biomarkers of Disease Activity and Severity
Mary Bach¹, Daniel Moon², Marcel Bach², Marcus Bach² and Christian Lood³, ¹VA Puget Sound Health Care System, Seattle, WA, ²University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration to joints participates in tissue destruction and development of…
Abstract Number: 248 • 2017 ACR/ARHP Annual Meeting
Validation of Objective Quantification System for Disease Progression in Patients with Juvenile Idiopathic Arthritis
Olga Kubassova¹, N Tzaribachev², Romiesa Hagoug³ and Mikael Boesen⁴, ¹R&D, Image Analysis Group, London, England, ²University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ³Imaging, Image Analysis Group, London, United Kingdom, ⁴Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiskberg, Denmark
Background/Purpose: Imaging as outcome measure has been studied and extensively used in the assessment of treatment for adult patients with rheumatoid arthritis (RA)1. In children…
Abstract Number: 682 • 2017 ACR/ARHP Annual Meeting
Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations
Thierry Dervieux¹, John Conklin¹, JoAnne Ligayon¹, Rowena Lafon², Armida Sace³, Tyler O'Malley⁴, Roberta Alexander¹ and Claudia Ibarra¹, ¹Exagen Diagnostics, Inc., Vista, CA, ²Immunochemistry, Exagen Diagnostics, Inc., Vista, CA, ³Automated Chemistry, Exagen Diagnostics, Inc., Vista, CA, ⁴Research and Development, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Abnormal activation of the complement system is emerging as a useful biomarker in the evaluation of patients presenting symptoms of autoimmune rheumatic diseases. We…
Abstract Number: 1181 • 2017 ACR/ARHP Annual Meeting
Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Jeong Seok Lee¹, Eun Young Lee², Jin Kyun Park³, Eun Bong Lee² and Yeong Wook Song⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁴Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Measuring severity of interstitial lung disease (ILD) usually depends on the extent or pattern of imaging findings on computed tomography (CT) and the parameters…
Abstract Number: 1708 • 2017 ACR/ARHP Annual Meeting
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Janine Schniering¹, Martina Benesova^2,3, Matthias Brunner⁴, Carol A. Feghali-Bostwick⁵, Roger Schibli^2,3, Oliver Distler⁶, Cristina Müller^2,3 and Britta Maurer⁶, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Chemistry and Applied Biosciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, Zurich, Switzerland, ³Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland, Villigen PSI, Switzerland, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a life-threatening complication in SSc. In recent years, distinct genomic and molecular subtypes in SSc-ILD were identified and molecular…
Abstract Number: 2362 • 2017 ACR/ARHP Annual Meeting
Novel Biomarkers for the Prediction of Subclinical Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis
Joan Bathon¹, Jenny Van Eyk², Nick Knowlton³, Ivan Ferraz-Amaro⁴, Jon T. Giles⁵, C. Michael Stein⁶, Mary Chester M. Wasko⁷ and Michael Centola⁸, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Advanced Clinical BioSystems Research Institute , Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Arthritis and Clinical Rheumatology, Oklahoma Medical Research Foundation, Oklahoma, OK, ⁴Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁵Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁷Lupus Center, Pittsburgh, PA, ⁸Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma, OK
Background/Purpose: Cardiovascular (CV) disease risk prediction models, that were originally developed for use in the general population, have been found to have suboptimal performance in…
Abstract Number: 2980 • 2017 ACR/ARHP Annual Meeting
Chemokine CCL21 As a Potential Serum Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis
Anna-Maria Hoffmann-Vold¹, Roger Hesselstrand², Håvard Fretheim¹, Thor Ueland¹, Arne K Andreassen¹, Oyvind Midtvedt¹, Torhild Garen¹, Pål Aukrust¹, John A Belperio³ and Øyvind Molberg¹, ¹Oslo University Hospital, Oslo, Norway, ²Lund University, Lund, Sweden, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose : Systemic sclerosis (SSc) is a major cause of pulmonary arterial hypertension (PAH). Murine models indicate key roles of chemokines CCL19/21 and their receptor…
Abstract Number: 414 • 2017 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission
Melanie Hagen¹, Matthias Englbrecht², Judith Haschka³, Michaela Reiser⁴, Arnd Kleyer⁵, Axel J. Hueber⁶, Bernhard Manger⁷, Camille Figueiredo⁸, Jayme Fogagnolo Cobra⁹, Hans-Peter Tony¹⁰, Stefanie Finzel¹¹, Stefan Kleinert¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Martin Feuchtenberger¹⁴, Martin Fleck^15,16, Karin Manger¹⁷, Matthias Schmitt-Haendle¹⁸, H.-M. Lorenz¹⁹, HG Nüßlein²⁰, Rieke Alten²¹, Joerg C. Henes²², Klaus Krüger²³, Georg Schett² and Juergen Rech²⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ³Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Department of Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Dept of Medicine 3, Rheumatology and Clinical Immunology, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁶Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Institution de Rheumatologia, Sao Paolo, Brazil, ⁹Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁰Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ¹¹University of Freiburg, Freiburg, Germany, ¹²Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, ¹⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ¹⁷Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁸Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁹Rheumatology, University Heidelberg, Heidelberg, Germany, ²⁰Rheumatology Practice Nuremberg, Nuremberg, Germany, ²¹Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ²²Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²³Praxiszentrum St.Bonifatius, Munich, Germany, ²⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 694 • 2017 ACR/ARHP Annual Meeting
Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Sung Soo Ahn¹, Younhee Park², Seung Min Jung¹, Jason Jungsik Song¹, Yong-Beom Park¹ and Sang-Won Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Abstract Background/Purpose : Serum Mac-2-binding protein (M2BP) is elevated in various chronic inflammatory diseases. Recently, the Wisteria floribunda agglutinin positive-M2BP (WFA+-M2BP) immunoassay has shown promise…
Abstract Number: 1187 • 2017 ACR/ARHP Annual Meeting
Chondroitin Sulfate/Glucosamine Hydrochloride Induce a Reduction in Adrenergic Serum Markers in Osteoarthritis Patients Similar to That Produced By Celecoxib
Marta Herrero¹, Pedro Zapater^2,3, Helena Martinez¹, Rubén Francés^3,4, Josep Vergés⁵ and Jose F Horga², ¹Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ²Pharmacology Department, Miguel Hernández University, Alicante, Spain, ³CIBERehd. Carlos III Institute, Madrid, Spain, ⁴Medicine Department, Miguel Hernández University, Alicantes, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain
Background/Purpose: Inflammation in osteoarthritis (OA) has been characterized by infiltration of immune cells and secretion of cytokines into synovial tissues. Noradrenaline levels, sympathetic nerve fiber…
Abstract Number: 1723 • 2017 ACR/ARHP Annual Meeting
Nuclear Magnetic Resonance Based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients
Sakir Ahmed¹, Mohit Kumar Rai¹, Durgesh Dubey², Atul Rawat³, Dinesh Kumar³, Durga Prasanna Misra¹ and Vikas Agarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Centre for Biomedical Research, PhD Student, Lucknow, India, ³Centre for Biomedical Research, Lucknow, India
Nuclear Magnetic Resonance based Metabolomics Study Identifies Highly Discriminatory Metabolites in 87 Systemic Sclerosis Patients Background/Purpose: Proton based Nuclear Magnetic Resonance (1H NMR) can identify…
Abstract Number: 2363 • 2017 ACR/ARHP Annual Meeting
Does Galectin-3 Have Utility As a Biomarker of Subclinical Cardiovascular Disease in RA Patients Independently of RA Disease Activity?
Amanda Nussdorf¹, Isabelle Amigues² and Joan Bathon³, ¹Columbia University Medical Center, New York, NY, ²Division of Rheumatology, Columbia University Medical Center, New York, NY, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Galectin-3 is a beta-galactoside-binding lectin and is a marker of cardiovascular disease (CVD) in the general population. However, galectin-3 level is also elevated in…
Abstract Number: 438 • 2017 ACR/ARHP Annual Meeting
High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
Jeffrey R. Curtis¹, Cecilie Heegaard Brahe², Mikkel Østergaard³, Merete Lund Hetland², Karen Hambardzumyan⁴, Saedis Saevarsdottir⁴, Xingbin Wang⁵, Eric H. Sasso⁵ and Tom W.J. Huizinga⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) test uses a validated algorithm with 12 serum protein biomarkers to assess disease activity in patients with RA. The…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Valentina Calamia¹, M Camacho¹, Ignacio Rego-Pérez¹, L González¹, P Fernández-Puente¹, F Picchi¹, Marta Herrero², Helena Martinez², C Ruiz-Romero¹ and Francisco J Blanco^3,4, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ³RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ⁴Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].